MX2024006168A - Composicion farmaceutica y uso de la misma. - Google Patents

Composicion farmaceutica y uso de la misma.

Info

Publication number
MX2024006168A
MX2024006168A MX2024006168A MX2024006168A MX2024006168A MX 2024006168 A MX2024006168 A MX 2024006168A MX 2024006168 A MX2024006168 A MX 2024006168A MX 2024006168 A MX2024006168 A MX 2024006168A MX 2024006168 A MX2024006168 A MX 2024006168A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
mutation
furmonertinib
egfr
Prior art date
Application number
MX2024006168A
Other languages
English (en)
Spanish (es)
Inventor
Qing Li
Huibing Luo
Original Assignee
Shanghai Allist Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Allist Pharmaceuticals Co Ltd filed Critical Shanghai Allist Pharmaceuticals Co Ltd
Publication of MX2024006168A publication Critical patent/MX2024006168A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024006168A 2021-11-24 2022-11-21 Composicion farmaceutica y uso de la misma. MX2024006168A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111404293.6A CN116159062A (zh) 2021-11-24 2021-11-24 药物组合物及其用途
PCT/CN2022/133171 WO2023093663A1 (en) 2021-11-24 2022-11-21 Pharmaceutical composition and use thereof

Publications (1)

Publication Number Publication Date
MX2024006168A true MX2024006168A (es) 2024-06-11

Family

ID=86416859

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024006168A MX2024006168A (es) 2021-11-24 2022-11-21 Composicion farmaceutica y uso de la misma.

Country Status (10)

Country Link
US (1) US20250017927A1 (https=)
EP (1) EP4436580A4 (https=)
JP (1) JP2024539476A (https=)
KR (1) KR20240124921A (https=)
CN (2) CN116159062A (https=)
AU (1) AU2022397653A1 (https=)
CA (1) CA3238480A1 (https=)
IL (1) IL312874A (https=)
MX (1) MX2024006168A (https=)
WO (1) WO2023093663A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024059962A1 (en) * 2022-09-19 2024-03-28 Shanghai Allist Pharmaceuticals Co., Ltd. Pharmaceutical composition and use thereof
CN116854694B (zh) * 2023-07-04 2024-07-09 北京浦润奥生物科技有限责任公司 [1,2,4]三唑[4,3-b]哒嗪化合物的晶型及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105315259B (zh) * 2014-07-29 2018-03-09 上海艾力斯医药科技有限公司 吡啶胺基嘧啶衍生物、其制备方法及应用
MX2022007969A (es) * 2019-12-23 2022-12-13 Blueprint Medicines Corp Inhibidores de egfr.
WO2023035223A1 (zh) * 2021-09-10 2023-03-16 上海艾力斯医药科技股份有限公司 药物组合物及其用途
WO2024059962A1 (en) * 2022-09-19 2024-03-28 Shanghai Allist Pharmaceuticals Co., Ltd. Pharmaceutical composition and use thereof

Also Published As

Publication number Publication date
IL312874A (en) 2024-07-01
JP2024539476A (ja) 2024-10-28
CN118678958A (zh) 2024-09-20
KR20240124921A (ko) 2024-08-19
EP4436580A1 (en) 2024-10-02
CA3238480A1 (en) 2023-06-01
US20250017927A1 (en) 2025-01-16
WO2023093663A1 (en) 2023-06-01
AU2022397653A1 (en) 2024-07-04
CN116159062A (zh) 2023-05-26
EP4436580A4 (en) 2025-09-24

Similar Documents

Publication Publication Date Title
MX2024012131A (es) Composicion farmaceutica, uso de la misma y metodo para tratar el cancer
MX2022015695A (es) Medicina de camptotecina con alta unidad de conexion hidrofila y conjugado de la misma.
MX2022010128A (es) Compuestos macrocíclicos y usos de estos.
WO2021243280A3 (en) Methods of treating cancer in patients with an anomalous kras gene or deletions within chromosome 9
WO2020102804A3 (en) Pharmaceutical combination for treatment of cancer
MX2024002822A (es) Composicion farmaceutica y uso de la misma.
MX2007004549A (es) Tratamiento combinado con bortezomib y un inhibidor de cinasa del receptor del factor de crecimiento epidermico.
MXPA03010121A (es) Terapia de combinacion que utiliza anticuerpos anti-receptor de factor de crecimiento epidermico y agentes anti-hormonales.
MX2024006168A (es) Composicion farmaceutica y uso de la misma.
CA2464758A1 (en) Combination therapy comprising zd6474 and a taxane
CA2902144A1 (en) Methods and compositions for treating cancers having acquired resistance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate
ZA202210640B (en) Deuterated oxophenylarsine compound and use thereof
MX2022006566A (es) Tratamientos conjuntos para tratamiento de cancer de mama.
Negi et al. Three weekly versus weekly cisplatin as radiosensitizer in head and neck cancer: a decision dilemma
MX2025002967A (es) Composicion farmaceutica y uso de la misma
CA2514227A1 (en) Combination therapy of zd6474 with 5-fu or/and cpt-11
IL164564A0 (en) Combination therapy for the treatment of cancer
TW200603804A (en) Treatment with irinotecan (cpt-11) and an EGFR-inhibitor
Nobile et al. A randomized trial of 5-fluorouracil alone versus 5-fluorouracil and high dose leucovorin in untreated advanced colorectal cancer patients
Giuliani et al. Maintenance therapy in colon cancer
MX2023005695A (es) Administracion de agonista de sting, inhibidores de puntos de control y radiacion.
MXPA04005207A (es) Metodos para tratar cancer utilizando un inhibidor de la farnesil proteina transferasa y agentes antineoplasticos.
TW200608959A (en) Treatment with oxaliplatin and an egfr-inhibitor
PH12021551951A1 (en) Combination therapies for use in treating cancer
Vokes Current treatments and promising investigations in a multidisciplinary setting